Standard
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. / Arribas, Jose R; Horban, Andrzej; Gerstoft, Jan; Fätkenheuer, Gerdt; Nelson, Mark Jason; Clumeck, Nathan; Pulido, Federico; Hill, Andrew; van Delft, Yvon; Stark, Thomas; Moecklinghoff, Christiane.
In:
AIDS, Vol. 24, No. 2, 16.01.2010, p. 223-30.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Arribas, JR, Horban, A
, Gerstoft, J, Fätkenheuer, G, Nelson, MJ, Clumeck, N, Pulido, F, Hill, A, van Delft, Y, Stark, T & Moecklinghoff, C 2010, '
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml',
AIDS, vol. 24, no. 2, pp. 223-30.
https://doi.org/10.1097/QAD.0b013e3283348944APA
Arribas, J. R., Horban, A.
, Gerstoft, J., Fätkenheuer, G., Nelson, M. J., Clumeck, N., Pulido, F., Hill, A., van Delft, Y., Stark, T., & Moecklinghoff, C. (2010).
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
AIDS,
24(2), 223-30.
https://doi.org/10.1097/QAD.0b013e3283348944Vancouver
Arribas JR, Horban A
, Gerstoft J, Fätkenheuer G, Nelson MJ, Clumeck N et al.
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
AIDS. 2010 Jan 16;24(2):223-30.
https://doi.org/10.1097/QAD.0b013e3283348944Author
Arribas, Jose R ; Horban, Andrzej ; Gerstoft, Jan ; Fätkenheuer, Gerdt ; Nelson, Mark Jason ; Clumeck, Nathan ; Pulido, Federico ; Hill, Andrew ; van Delft, Yvon ; Stark, Thomas ; Moecklinghoff, Christiane. / The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. In: AIDS. 2010 ; Vol. 24, No. 2. pp. 223-30.
Bibtex
@article{ea73939b67a64c619f4ec53549db94d1,
title = "The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml",
abstract = "In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.",
author = "Arribas, {Jose R} and Andrzej Horban and Jan Gerstoft and Gerdt F{\"a}tkenheuer and Nelson, {Mark Jason} and Nathan Clumeck and Federico Pulido and Andrew Hill and {van Delft}, Yvon and Thomas Stark and Christiane Moecklinghoff",
year = "2010",
month = jan,
day = "16",
doi = "http://dx.doi.org/10.1097/QAD.0b013e3283348944",
language = "English",
volume = "24",
pages = "223--30",
journal = "AIDS",
issn = "1350-2840",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "2",
}
RIS
TY - JOUR
T1 - The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
AU - Arribas, Jose R
AU - Horban, Andrzej
AU - Gerstoft, Jan
AU - Fätkenheuer, Gerdt
AU - Nelson, Mark Jason
AU - Clumeck, Nathan
AU - Pulido, Federico
AU - Hill, Andrew
AU - van Delft, Yvon
AU - Stark, Thomas
AU - Moecklinghoff, Christiane
PY - 2010/1/16
Y1 - 2010/1/16
N2 - In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.
AB - In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.
U2 - http://dx.doi.org/10.1097/QAD.0b013e3283348944
DO - http://dx.doi.org/10.1097/QAD.0b013e3283348944
M3 - Journal article
VL - 24
SP - 223
EP - 230
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 2
ER -
